Hemab Therapeutics’ principal executive offices are located at 101 Main Street, Suite 1220, Cambridge, MA 02142. Hemab Therapeutics also maintains operations in Copenhagen, Denmark at Nordre Fasanvej 215, 2000 Fredericksberg, Denmark.
Hemab Therapeutics was incorporated under the laws of the State of Delaware in February 2026. Hemab Therapeutics previously operated as Hemab ApS, a private limited company organized under the laws of the Kingdom of Denmark.
Hemab Therapeutics’ fiscal year ends December 31st.
Hemab Therapeutics’ common stock is listed on the Nasdaq Global Select Market under the symbol “COAG”.
The auditor for Hemab Therapeutics is EY Godkendt Revisionspartnerselskab.
Legal counsel for Hemab Therapeutics is Wilmer Cutler Pickering Hale and Dorr LLP.
The transfer agent and registrar for the common stock of Hemab Therapeutics is:
Computershare Trust Company, N.A.
P.O. Box 43006
Providence, RI, 02940-3006
800-736-3001
For questions related to your common stock, please contact Computershare Trust Company, N.A.
To find out more about Hemab Therapeutics visit our webpage at www.Hemab.com.
Hemab Therapeutics’ press release archive can be viewed under the “News Releases” section of the “Investors” page and financial reports are available under the “SEC Filings” section located at its website: www.hemab.com.
Hemab Therapeutics’ SEC Filings can be found on www.sec.gov and are also available under the “SEC Filings” section of the “Investors” page located at our website www.hemab.com.
For investor inquiries please contact investors@hemab.com.
Phone: +1 800-236-0176
Portal: https://www.whistleblowerservices.com/COAG